Who raised, how much, from whom, and what the money is for. Device startups only.
| Date | Company | Amount | Stage | Lead |
|---|---|---|---|---|
| Sep 2, 26 | Elucid | $55M | Series D | Not named |
| Aug 19, 26 | Renata Medical | $25M | Series D | ARCHIMED |
| Aug 6, 26 | Meduloc | $4M | Series B | GenHenn Capital |
| Jul 28, 26 | Aurenar | $5.7M | Seed | Go Red for Women Venture Fund (American Heart Association Ventures) and Solas BioVentures (co-leads) |
| Jun 9, 26 | GT Medical Technologies | $100M | Series E | Viking Global Investors |
| Jun 4, 26 | CereVasc | $85M | Series C (initial close) | Piper Sandler Merchant Banking |
| Jun 1, 26 | Veritas Aortic Solutions | $12M | Seed | Group of medtech angel investors |
| May 18, 26 | MiRus | $1.5B | Strategic investment | Boston Scientific |
| May 7, 26 | Mobia Medical | $150M | IPO | BofA Securities, J.P. Morgan and Goldman Sachs (bookrunners) |
| Apr 29, 26 | Aidoc | $150M | Series E | Growth Equity at Goldman Sachs Alternatives |
| Apr 29, 26 | Axoft | $55M | Series A | C.P. Group Innovation |
| Apr 29, 26 | Hypervision Surgical | £17M (about $23M) | Series A | Heal Capital |
Elucid closed a $55M Series D on September 2, 2026, backed by a fourth public medtech strategic, IAG Capital Partners and Elevage Medical Technologies. Total funding for the Boston company reaches about $185M as its BioIntegrated FFR-CT 510(k) sits under FDA review.
Renata Medical closed a $25M Series D led by ARCHIMED on August 19, 2026. The Newport Beach, CA company's Minima pediatric stent, approved under PMA P240003 in August 2024, gets money for US expansion and international entry.
Meduloc closed a $4M Series B led by GenHenn Capital on August 6, 2026. The West Chester, PA company's nitinol Intramedullary Fracture Fixation System, cleared under K250316 in October 2025, enters a controlled alpha launch this month.
Aurenar closed an oversubscribed $5.7M seed round on July 28, 2026, co-led by the AHA's Go Red for Women Venture Fund and Solas BioVentures. Its V-Link ear-worn vagus nerve stimulator for vasospasm after subarachnoid hemorrhage got FDA Breakthrough designation on June 30.
GT Medical Technologies closed an oversubscribed $100M Series E led by Viking Global Investors on June 9, 2026, bringing total funding to $214M. Its GammaTile brain brachytherapy implant cut 12-month surgical-bed recurrence to 1.3% from 15.4% in the ROADS trial.
CereVasc closed an initial $85M Series C led by Piper Sandler Merchant Banking on June 4, 2026, with J&J's JJDC and Medtronic both investing. The Boston company is running the STRIDE trial of eShunt, an endovascular CSF shunt for normal pressure hydrocephalus.
Veritas Aortic Solutions, an inQB8 Medical Technologies spinout in Costa Mesa, CA, closed a $12M seed round on June 1, 2026. Medtech angel investors led, with Cedars-Sinai Intellectual Property Company joining, to take the TVARC aortic root implant to first-in-human use.
Boston Scientific announced a $1.5B investment in MiRus on May 18, 2026, buying about 34% of the company. It also holds an option on the rest of MiRus's TAVR business, whose nickel-free SIEGEL valve has entered a 1,025-patient approval trial.
Mobia Medical, the renamed MicroTransponder, priced its IPO at $15 a share on May 7, 2026, selling 10 million shares for $150M gross. Its Vivistim stroke implant, approved under PMA P210007 in 2021, brought in $32M of revenue in 2025.
Aidoc announced a $150M Series E led by Growth Equity at Goldman Sachs Alternatives on April 29, 2026, taking total funding past $500M. The radiology AI company runs in nearly 2,000 hospitals and holds more than 30 FDA 510(k) clearances.
Axoft closed an oversubscribed $55M Series A led by C.P. Group Innovation on April 29, 2026. The Cambridge, MA company has implanted its Fleuron-based brain-computer interface in 11 or more patients and will build a GMP plant in Boston.
Hypervision Surgical closed a £17M (about $23M) Series A led by Heal Capital on April 29, 2026. Its HyperSnap Surgical System was cleared under K250268 in June 2025 with a new product code for AI-based video augmentation in surgery.
Endovascular Engineering (E2) closed an oversubscribed $80M Series C co-led by Gilde Healthcare and Norwest on April 7, 2026. The Menlo Park company will build a sales force for Hēlo, its thrombectomy catheter cleared under K252956 in December 2025.
Endogenex closed a $50M Series C extension on March 25, 2026, led by new investor Arboretum Ventures. The Series C now totals $138M and funds the sham-controlled study of ReCET, its endoscopic pulsed electric field therapy for type 2 diabetes.
Vitestro closed an oversubscribed $70M Series B on March 10, 2026, with Labcorp Venture Fund, Mayo Clinic and Sutter Health among new investors. The Utrecht company will use it for a De Novo submission and US scale-up of Aletta, its autonomous blood-draw robot.
Cognito Therapeutics closed an oversubscribed $105M Series C on March 5, 2026, co-led by Morningside Ventures, IAG Capital Partners and Starbloom Capital. The money carries its Spectris gamma stimulation device for Alzheimer's through HOPE trial data, an FDA submission and a 2027 launch.
Neurent Medical closed an oversubscribed 62.5 million euro ($74 million) Series C on February 11, 2026. MVM Partners led, with Sofinnova Partners joining as a new investor. The Galway company's NEUROMARK radiofrequency system has held 510(k) clearance since October 2021.
Inquis Medical closed a $75 million Series C on January 12, 2026, funded by an undisclosed strategic investor. The Menlo Park company's Aventus thrombectomy system has a string of 510(k)s, including the June 2025 pulmonary embolism clearance under K251189.
Ventaris Surgical closed a $30 million Series A led by Longitude Capital on January 9, 2026, with Vensana Capital joining as a new investor. The San Carlos company is developing a ureteroscopic system aimed at complete kidney stone clearance in a single procedure.
Spiro Medical closed a $67 million Series A led by Andera Partners on January 7, 2026, with Omega Funds and Sherpa Healthcare Partners co-leading. The Irvine startup, which surfaced in 2025, is developing a Pulmonary Neuromodulation System for severe asthma.
Biobeat Technologies closed a $50 million Series B co-led by Ally Bridge Group, OrbiMed and Elevage Medical on December 30, 2025. The Israeli company's chest patch, cleared under K241066 in January 2025, measures ambulatory blood pressure without a cuff.
Akura Medical closed the first $53 million of a Series C led by the Qatar Investment Authority on December 1, 2025. The Shifamed portfolio company will finish enrolling the QUADRA-PE trial of its Katana thrombectomy system and set up a joint venture in Qatar.
Cordance Medical closed an oversubscribed seed round of more than $8 million led by Sonder Capital, announced November 24, 2025. The Mountain View company holds an FDA Breakthrough Device designation in neuro-oncology and is planning its first-in-human trial.
Okami Medical closed a $45 million financing led by new investor Gilde Healthcare on November 19, 2025, with Vensana Capital and U.S. Venture Partners returning. The Aliso Viejo company also named former Inari Medical CEO Drew Hykes president and CEO.
Distalmotion closed a $150 million Series G led by Revival Healthcare Capital on November 18, 2025. The Lausanne company also named former Silk Road Medical CEO Chas McKhann executive chairman as it targets U.S. ambulatory surgery centers with the Dexter robot.
Beacon Biosignals closed an oversubscribed $86 million Series B on November 13, 2025, with six co-leads including Innoviva, GV and Takeda. The Boston company's Waveband headband, formerly Dreem 3S, holds three 510(k)s.
Synchron closed a $200 million Series D led by Double Point Ventures on November 6, 2025, bringing total funding to $345 million. The New York company will use it for late-stage trials and launch preparation for the Stentrode endovascular brain-computer interface.
London neurotech CoMind announced $102.5 million in total funding on October 20, 2025, with the new $60 million Series A led by Plural. The money goes to U.S. regulatory work on CoMind One, a non-invasive bedside brain monitor.
HistoSonics closed an oversubscribed $250 million growth financing on October 16, 2025. Its new ownership group led, two months after buying a majority stake at a $2.25 billion valuation.
Jupiter Endovascular closed an oversubscribed Series B above its $40 million target on October 7, 2025, led by Sonder Capital. FDA cleared the company's Vertex catheter under K252027 on September 12, 74 days after receipt.
Shanghai-based Ronovo Surgical closed a $67 million Series D led by JJDC, Johnson & Johnson's venture arm, announced September 5, 2025. The round came with a commercial agreement with J&J MedTech in China for the Carina laparoscopic robot.
Galvanize Therapeutics closed an oversubscribed $100 million Series C led by Sofinnova Partners on September 3, 2025. The Redwood City company also named former Shockwave CEO Doug Godshall as chairman and CEO.
New clearances, funding rounds and regulatory moves for device founders. No noise, no login.
You're in. The next morning brief lands in your inbox.